Pomegra
Corteva (CTVA) shares fell about 20% after Q3 2026 revenue of $1.59B missed the $1.77B estimate, as Brazil weakness and acetochlor pricing cut guidance.
- Q3 net sales were $1.59B, down 9% year over year and about 10% below the $1.77B consensus.
- Adjusted EPS of $0.06 missed the $0.10 estimate; adjusted EBITDA fell 17% to $222M.
- Full-year EBITDA guidance now stands at $1.1B-$1.125B, a decline of roughly 12% at the midpoint.
Lead
Corteva (NYSE: CTVA) shares dropped roughly 20% on Thursday, November 12, 2026, after the crop protection company reported third-quarter revenue of $1.59B, below the $1.77B consensus. The stock closed at $12.14 before the report and fell to about $9.26 at its worst, close to its 52-week low of $9.14. Results were released after the close on November 11 and are the first quarterly figures since the company separated its seed business into Vylor Inc. (VYLR) on October 1.What Happened to Corteva Stock After the Earnings Report?
Corteva stock sold off by about a fifth in heavy trading, with the intraday low near $9.26. The decline followed a miss on both revenue and profit. Adjusted pro forma operating EPS came in at $0.06 against the $0.10 estimate, and pro forma GAAP EPS was a loss of $0.08 per share. Pro forma GAAP income from continuing operations was a loss of $54M, against a profit of $60M in the same quarter a year earlier.
Net sales fell 9% on both a reported and organic basis. Adjusted pro forma operating EBITDA was $222M, down 17%, and the margin narrowed 140 basis points to 14.0%.
Why Did Corteva Miss Q3 Estimates?
Corteva missed because Latin America, and Brazil in particular, weakened far more than expected, while pricing pressure on acetochlor cut into the gains from new products. Latin American sales fell 28% to $570M, with volume down 24% and price down 7%. Conditions in Brazil included elevated channel inventories, delayed purchasing by growers, high interest rates and an unfavorable currency backdrop.
Pricing was the second drag. The quarter carried a $119M price headwind, and about 90% of it came from U.S. acetochlor and Latin America, where generic competition has followed the loss of patent protection on the herbicide.
Other regions were firmer:
- North America: sales rose 7% to $574M. Volume grew 19%, but price and mix fell 12%.
- EMEA: sales rose 12% to $239M on 14% volume growth from new products.
- Asia Pacific: sales rose 3% to $208M, with volume up 7% and price down 2%.
New products lifted volumes by about 20% across regions, led by the Arylex herbicide. That was not enough to offset Latin America and pricing.
How Does the Separation Shape the Results?
The separation makes this quarter harder to compare, and it explains why the figures are presented on a pro forma basis. On October 1, 2026, Corteva distributed all shares of its seed business, now Vylor Inc., to shareholders through a pro rata dividend. Corteva continues to trade under CTVA as a pure-play crop protection company.
The third quarter is also the smallest of the year for the agricultural calendar, so revenue misses can look larger in percentage terms. Year-to-date net sales stand at $5.4B, down 1% reported and 4% organic. Year-to-date EBITDA of $943M is flat, with a margin of 17.6%.
Strategic Context
The quarter shows the risks of a stand-alone crop protection business. Its earnings depend on pricing in off-patent molecules and on Brazil, which is one of the largest crop input markets in the world. Corteva's reliance on new differentiated products is the main counterweight to generic pricing, and the 20% volume growth from those products shows demand for them. Management's pricing assumptions for acetochlor and its outlook for Brazilian credit conditions are now the central variables for the stock.
What Comes Next for Corteva?
The next test is whether the Brazil weakness proves temporary or lasts into the 2027 season. Corteva lowered full-year 2026 adjusted pro forma operating EBITDA guidance to $1.1B-$1.125B, a decline of about 12% at the midpoint, with an operating margin near 15%. Adjusted pro forma operating EPS is now forecast at $0.76-$0.80.
The implied fourth quarter leaves little margin for further pricing erosion. Channel inventory levels in Brazil, farmer credit availability and the pace of generic competition on acetochlor are the indicators that will set the direction of results into 2027.
Outlook
Corteva delivered a quarterly revenue miss of about 10%, a 17% drop in adjusted EBITDA and a lower full-year forecast in its first report after the Vylor separation. Growth in North America, EMEA and Asia Pacific, together with strong uptake of new products, was overwhelmed by a 28% fall in Latin American sales and a $119M pricing headwind. The roughly 20% share price decline leaves CTVA near its 52-week low as investors wait for evidence that Brazil and pricing are stabilizing.
Mentioned tickers: CTVA, VYLR
